PeptideDB

Imisopasem manganese

CAS: 218791-21-0 F: C21H31Cl2MnN5 W: 479.35

Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD.
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD.
Invitro Imisopasem manganese is a small molecule, synthetic manganese containing superoxide dismutase mimetic (SODm) that removes superoxide anions without interfering with other reactive species known to be involved in inflammatory responses (e.g. nitric oxide, NO and peroxynitrite, ONOO-)[1].
In Vivo Imisopasem manganese is a small-molecule superoxide dismutase mimetic that has shown efficacy in animal model disease states in which superoxide anions are thought to play a key role. Imisopasem manganese inhibits the inflammatory response following the intrapleural injection of carrageenan in rats. All parameters of inflammation are attenuated by Imisopasem manganese except for NOx, PGE2 and IL-10 which remains unaltered[1]. Decreased apoptosis of the large and particularly the small bowel and marked recovery of both lymphoid and hematopoietic tissues occurs in the Imisopasem manganese pre-treated mice. Imisopasem manganese is effective in reducing TBI-induced tissue destruction and has potential as a new radioprotective agent[2].
Name Imisopasem manganese
CAS 218791-21-0
Formula C21H31Cl2MnN5
Molar Mass 479.35
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Salvemini D, et al. Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic,M40403. Br J Pharmacol. 2001 Feb;132(4):815-27. [2]. Masini E, et al. Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo. Br J Pharmacol. 2002 Jul;136(6):905-17.